Skip to content

INSPIRE-CF: an Alternative Physiotherapy Model for Children With Cystic Fibrosis

INSPIRE-CF: A Randomised Controlled Trial Investigating the Clinical and Economic Benefits of an Alternative Model of Physiotherapy Care for Children With Cystic Fibrosis

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01889927
Acronym
INSPIRE-CF
Enrollment
71
Registered
2013-07-01
Start date
2012-05-01
Completion date
2017-12-31
Last updated
2019-09-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cystic Fibrosis

Keywords

exercise, physiotherapy, lung function, quality of life

Brief summary

The primary aim of the research is to evaluate whether an alternative model of cystic fibrosis (CF) physiotherapy care can produce statistically significant improvements in clinical and patient reported outcomes, and whether this alternative model is economically advantageous and/or sustainable. Children randomised to the control group will receive 24-months of current model of CF care at Great Ormond Street Hospital (GOSH). Children randomised to the intervention group will receive 24-months of current model of CF care at GOSH PLUS a weekly structured, individually prescribed and personally supervised exercise intervention at a local fitness facility or at school. The exercise prescription will include aerobic, anaerobic, strength, core conditioning and stretching components. The main objectives of the study are: 1. Determine differences, if any, in lung function between the two groups; 2. Determine differences, if any, in exercise capacity between the two groups; 3. Evaluate cost of care of alternate model of care versus current model of care.

Interventions

OTHERExercise Intervention

The exercise intervention will include aerobic, anaerobic, strength, core conditioning and stretching components.

Sponsors

Great Ormond Street Hospital for Children NHS Foundation Trust
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
6 Years to 15 Years
Healthy volunteers
No

Inclusion criteria

* Patients with a documented diagnosis of Cystic Fibrosis; * Male or female aged 6 years or older at baseline and \<17years old at the end of the 2-year study; * Currently under the primary care of the GOSH CF Unit; * Able to perform Spirometry with a baseline FEV1 percentage predicted of 40% or higher, as measured on at least 3 occasions in the previous year, during times of clinical stability (i.e. not during an exacerbation, and not during or within 2 weeks of intravenous antibiotics); * The participant's parent or legal guardian must be able to give informed consent; assent will be sought from all children.

Exclusion criteria

* Patients who have had lung transplantation; * Patients listed for lung transplantation; * Clinically significant disease or medical condition other than CF or CF-related conditions that in the opinion of the multi-disciplinary clinical team, would compromise the safety of the patient; * Orthopaedic impairment that compromises exercise performance; * Mental impairment leading to inability to cooperate; * Unable to understand both verbal and/or written instructions English. Children will need to be able to understand exactly what the physiotherapists are instructing them do, for safe and effective exercise training sessions. Information sheets and questionnaires are only available in English; * Participants, parents or legal guardians who are unwilling to sign consent to participate in the study. The following criteria will not exclude a child from participating in the study, but based on the hospital's exercise laboratory's infection control protocol, may preclude the participant from Cardiopulmonary Exercise Testing. * Patients with Methicillin-Resistant Staphylococcus Aureus; * Patients with Burkholderia Cepacia.

Design outcomes

Primary

MeasureTime frameDescription
Forced expiratory volume in one second (FEV1)Baseline, 6, 12 and 24-month intervals.Spirometry data will also to be collected at outpatient clinics, annual reviews and during hospital admissions.

Secondary

MeasureTime frameDescription
Peak oxygen uptake (VO2Peak)Baseline, 12 and 24-month intervalsGold standard exercise test to determine peak oxygen uptake during exercise
10m-Modified Shuttle Walk TestBaseline, 6, 12 and 24 monthsField test to assess functional exercise capacity. Distance covered and incremental level changes are evaluated over time.
Lung Clearance IndexBaseline, 12 and 24 monthsMultiple breath washout test to evaluate for changes in small airways
Height, weight, body mass index measurementsBaseline, 6, 12 and 24 monthsHeight, weight and body mass index will be measured at regular intervals to evaluate for changes in growth parameters
Cystic Fibrosis QuestionnaireBaseline, 12 and 24 monthsDisease specific questionnaire to evaluate changes in quality of life in cystic fibrosis
Cost of careBaseline, 12 and 24 monthsEvaluate differences in cost of care between the current model of CF care and the alternative model of care; and cost per patient.

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026